Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IgG4-TREAT

Financiado

Cerrado

Systematic study of IgG4-autoimmune diseases to develop new treatment strategies

IgG4-autoimmune diseases (IgG4-AID) are rare but collectively correspond to a significant group of devastating diseases affectingmany different organs, e.g. skin, brain, nerves and kidney in patients that often remain unresponsive... ver más

31/08/2027

MEDIZINISCHE UNIVE...

Presupuesto desconocido

Líder del proyecto

MEDIZINISCHE UNIVERSITAET WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-09-01

HORIZON-MSCA-2022-DN-01-01: MSCA Doctoral Networks 2022 Expected Outcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

MEDIZINISCHE UNIVERSITAET WI...

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 47 meses Fecha Inicio: 2023-09-01
Fecha Fin: 2027-08-31

Líder del proyecto

MEDIZINISCHE UNIVERSITAET WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto IgG4-autoimmune diseases (IgG4-AID) are rare but collectively correspond to a significant group of devastating diseases affectingmany different organs, e.g. skin, brain, nerves and kidney in patients that often remain unresponsive to current treatments. IgG4-AIDhave commonalities indicating a shared underlying immunopathogenesis that make a joint approach to identify new therapeutictargets and test new treatment strategies feasible and necessary. We hypothesize that genetic risk factors and a dysregulatedimmune response may lead to an increased susceptibility to produce antibodies targeting self-proteins. These are of a specialsubclass called IgG4, which are usually harmless but can cause disease in these patients by interfering with normal functions in thebody. We are the first consortium that aims to study IgG4-AID comparatively, including pathogenic IgG4, and the cells, molecules andmechanisms involved in IgG4 autoantibody production, using an explorative multi-omics approaches in combination with state-ofthe-art cell and molecular biology methodology. We will establish a new humanized mouse model of IgG4-AID for the developmentand testing of a novel immune-apheresis based therapy aimed as immediate relief therapy for all IgG4-AID patients. Our innovativetraining program combines university-based and multidisciplinary research-based training with state-of the art web-based trainingand in-person trainings by the academic and non-academic sector. We aim to foster a new generation of experts in IgG4-AID that are1) are highly employable both in the academic and industry sectors and qualified for innovative multidisciplinary translationalresearch with a focus on biomedical product development and 2) equipped with the skillsets for digitalization, awareness for genderequality and diversity and competent in sustainable research and innovation approaches to address current and future challenges,such as climate change, social inequalities and pandemics.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores